ArticleScientific reports2026
A unified multi modal transformer framework for breast cancer recurrence prediction and survival analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Breast cancer recurrence prediction is an important feature of post-treatment therapy, requiring accurate identification of both recurrence risk and time-to-event outcomes. In this paper, we offer a unified deep learning system that jointly performs survival analysis and multi-class recurrence classification, enabling full risk stratification for breast cancer patients. The proposed model includes a Transformer-based survival module to estimate time-until-recurrence, and an attention-guided classification module to differentiate between second primary cancer, low-risk, and high-risk recurrence instances. A multi-modal dataset comprising clinical, molecular, demographic, and lifestyle data is created from established sources like METABRIC, GSE2034, GSE2990, BCSC, and the Breast Cancer Coimbra dataset. The model uses cross-modal feature fusion, autoencoder-based dimensionality reduction, and attention-based feature attribution for applicability and accessibility. Experimental results show better accuracy, precision, recall, and F1-score of 99.12%, 98.75%, 99.08%, and 98.91%, outperforming standard machine learning and survival models. This unified paradigm gives doctors a powerful, interpretable tool for early intervention and personalized breast cancer treatment.
Indexed as
Identifiers
41673422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.